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Abstract
 
Long-lived humoral immunity is manifested by the ability of bone marrow plasma cells (PCs)
to survive for extended periods of time. Recent studies have underscored the importance of
BLyS and APRIL as factors that can support the survival of B lineage lymphocytes. We show
that BLyS can sustain PC survival in vitro, and this survival can be further enhanced by inter-
leukin 6. Selective up-regulation of Mcl-1 in PCs by BLyS suggests that this 
 
 
 
-apoptotic gene
product may play an important role in PC survival. Blockade of BLyS, via transmembrane activator
and cyclophilin ligand interactor–immunoglobulin treatment, inhibited PC survival in vitro
and in vivo. Heightened expression of B cell maturation antigen (BCMA), and lowered expression
of transmembrane activator and cyclophilin ligand interactor and BAFF receptor in PCs relative
to resting B cells suggests a vital role of BCMA in PC survival. Affirmation of the importance
of BCMA in PC survival was provided by studies in BCMA
 
 
 
/
 
 
 
 mice in which the survival of
long-lived bone marrow PCs was impaired compared with wild-type controls. These findings
offer new insights into the molecular basis for the long-term survival of PCs.
Key words: B lymphocyte subsets • antibody formation • cell differentiation • 
cell lineage • immunophenotyping
 
Introduction
 
The persistence of plasma cells (PCs) within the BM is
supported by soluble factors and cell–cell contact (1). The
stroma contributes both soluble survival signals, such as IL-6,
as well as cell contact–mediated signals (e.g., through the
PC adhesion receptor, VLA-4; references 1, 2). In addition
to stromal elements, PCs interact with various other BM
resident cells, including developing lymphoid and myeloid
lineage cells. The overall impact of these interactions is to
support the longevity of the PC. Intrinsic qualities, such as
increased expression of the antiapoptotic factors (e.g., Mcl-1,
Bcl-xL, Bcl-2, Bim, and BCL-w) and decreased expression
of the pro-apoptotic factors Bax and BID, may contribute
to the long term survival of BM PCs (3). Deletion or enforced
expression of certain factors, such as Bim and Bcl-2, by
gene targeting have been shown to significantly alter PC
survival (3–5).
A recently identified member of the TNF superfamily,
BLyS (also referred to as BAFF, TALL-1, THANK,
zTNF4, and TNFS13B), plays an integral role in the devel-
opment of mature B cells (for review see reference 6).
BLyS binds to three receptors of the TNF receptor family
(B cell maturation antigen [BCMA], transmembrane activator
and cyclophilin ligand interactor [TACI], and BAFF-R), all
of which are expressed by mature B cells (6, 7). A deficiency
in either BLyS or BAFF-R results in a severely diminished
pool of mature B lymphocytes within the periphery (8–10),
suggesting that the BLyS/BAFF-R axis is critical for B cell
maturation. On the other hand, loss of the TACI receptor
results in an enhanced number of peripheral B lymphocytes
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coupled with an inhibited T cell–independent (TI) re-
sponse (6, 11). More recently, it has been shown that loss
of TACI results in the development of autoimmunity, sug-
gesting a negative regulatory role to this receptor (12).
These observations have led to the idea that TACI func-
tions as a negative regulator of the BLyS/BAFF-R B cell
maturation axis. The function of the third receptor,
BCMA, which is primarily restricted to the B cell lineage
(6), remains unresolved. A comprehensive analysis of
BCMA
 
 
 
/
 
 
 
 mice by Xu and Lam have shown that loss of
the BCMA receptor does not impact on the generation
of mature peripheral B cells, alter the quality or magnitude
of TI and T cell–dependent (TD) humoral immune re-
sponses, nor alter germinal center (GC) formation or the
generation of short-lived PCs (13). Thus, previous analyses
have not yet identified a function for the BCMA receptor.
Although BLyS clearly sustains the peripheral mature B
cell pool, a requirement of BLyS for terminally differenti-
ated B cells has not yet been fully resolved. Do et al. (14)
have reported that BLyS may function in supporting GC B
cell survival in vivo; however, it remains unclear whether
BLyS affects the development and/or survival of memory
B cells or long-lived PCs from GC B cells. However, a re-
cent work implicates BLyS as a regulator of short-lived PC
emergence resulting from TI responses within the marginal
zone (MZ) of the spleen (15). Blockade of BLyS via TACI-
Ig results in a loss of plasmablasts from MZ B cells in vitro
and in vivo. Specialized CD11c
 
low
 
 blood DCs provide MZ
B cells with BLyS, which enhances B cell survival but not
proliferation. These observations are consistent with the
observations that activated macrophages and DCs express
BLyS (16). The loss of plasmablast formation with TACI-
Ig treatment reflects increased apoptosis of the MZ B cell
population. Thus, BLyS is necessary for terminal differenti-
ation of MZ B cells in TI responses. The importance of
BLyS in supporting the terminal differentiation of B cells
has been further evidenced by recent in vitro studies show-
ing that BLyS selectively enhances the survival of plasma-
blasts generated from human memory cells (17). APRIL, a
close relative of BLyS, also binds to BCMA and TACI, but
not BAFF-R. Both BLyS and APRIL have been shown to
signal through TACI and BCMA, and each ligand en-
hances Ig production from B cells (18). However, little is
known about the function of APRIL in the regulation of
humoral immune responses.
This paper shows that the survival of long-lived BM PCs
can be sustained by recombinant BLyS or APRIL and IL-6
in vitro. Enhanced survival is correlated with an increase in
Mcl-1 transcript levels in PCs stimulated with BLyS. Fur-
thermore, in BM cultures containing PCs, the blockade by
TACI-Ig of these ligands facilitates the decay of long-lived
PCs. After the immunization and development of long-
lived BM PCs, treatment with TACI-Ig causes a decay of
this established PC population. Furthermore, we demon-
strate that BM PCs express heightened mRNA for the
BCMA receptor, but not TACI or BAFF-R compared
with naive B cells. Confirmation that BCMA is the receptor
 
on PCs critical for their survival is demonstrated by the re-
duced number of long-lived BM PCs in BCMA
 
 
 
/
 
 
 
 mice
compared with WT mice. We hypothesize that BLyS or
APRIL expression within the BM, via triggering of BCMA
on PCs, is critical for long-lived PC survival.
 
Materials and Methods
 
Mice and Reagents.
 
10–12-wk-old BALB/c and C57BL/6
(Jackson Laboratory) mice were maintained in the specific patho-
gen-free animal facility at Dartmouth Medical School. BCMA
 
 
 
/
 
 
 
mice were provided by J. Gross (Zymogenetics, Seattle, WA).
The following monoclonal antibodies were used for our stud-
ies: rat IgG
 
2a
 
 anti–mouse B220 (clone RA3-6B2) and rat IgG
 
2a
 
anti–mouse CD138 (Syndecan-1, clone 281-2; BD Biosciences).
The anti-Ly6C antibody was provided by T. Waldschmidt (Uni-
versity of Iowa, Iowa City, IA), and the soluble TACI-Ig was
generated as described previously (19). To produce soluble BLyS,
Flag-tagged human BLyS (amino acid 141-285) was expressed in
 
Pichia pastoris 
 
(EasySelect™ Pichia Expression Kit; Invitrogen), and
protein was purified on an anti-Flag affinity column. Streptavi-
din-CyChrome was obtained from BD Biosciences. Recombi-
nant APRIL was purchased from US Biological.
 
Immunization.
 
Mice were challenged s.c. with 10 
 
 
 
g PE (Cy-
anotech Corp.) or KLH (Sigma-Aldrich) emulsified in CFA. For
experiments in BCMA
 
 
 
/
 
 
 
 mice, mice were immunized with
100 
 
 
 
g of alum-precipitated (4-hydroxy-3-nitrophenyl)acetyl
chicken 
 
 
 
 globulin (Biosearch Technologies) i.p. After 51 d, the
animals were killed, and BM was isolated.
 
In Vitro Culture.
 
Cells were cultured in complete RPMI
1640 supplemented with 10% FBS containing IL-6 and/or solu-
ble BLyS and/or soluble TACI-Ig for 4–10 d. At the end of the
culture, cells were harvested and either enumerated for PCs by
ELISPOTs or stained for PC markers (CD138 and Ly6C.)
 
FACS
 
®
 
 Analysis and Sorting.
 
Cells were washed in 5% FCS
in balanced salt solution (BSS) and resuspended in low-pH (pH
4.0) acetate buffer containing 0.05 M sodium acetate, 0.085 M
NaCl, and 0.005 M KCl and 2% FCS in distilled H
 
2
 
O for re-
moval of cytophilic Ig. Samples were incubated on ice for 1 min
followed by the addition of an equal volume of 0.1 M Tris buffer,
pH 8.0, containing 2% FCS. Samples were washed twice in 5%
FCS BSS and stained. Chromatographically purified rat IgG was
used as isotype control. For all studies, nonspecific staining was
further reduced by the addition of heat-inactivated rat serum. In-
cubation with biotinylated antibodies was followed by incubation
with streptavidin, peridinine chlorophyll protein, or CyChrome
or allophycocyanin (BD Biosciences). Antibody incubations were
for 30 min at 4
 
 
 
C followed by washing in BCS/BSS. A minimum
of 500,000 events per sample were collected on a FACScan™, and
dead cells were excluded based on forward and 90
 
 
 
 light scatter.
Data were analyzed with FlowJo software. In case of cell sorting,
PCs (CD138
 
 
 
Ly6C
 
 
 
B220
 
 
 
) were sorted from CD138
 
 
 
 BM cells
using the automatic cell–dispensing unit attached to the FACStar-
PLUS™ (Becton Dickinson).
 
ELISPOT Assay.
 
BM IgG-secreting cells were enumerated
by an antigen-specific ELISPOT assay as described previously
(20). In brief, BM PE or NP-specific IgG antibody-secreting cells
(ASCs) were enumerated by an IgG ELISPOT assay. After isola-
tion of BM cells, RBCs were lysed via incubation with ammo-
nium chloride Tris, and T cells were depleted through anti–Thy-
1.2 microbeads (Miltenyi Biotec). Of the remaining population,
2.4 
 
 
 
 10
 
6
 
 cells/well were apportioned to PE or NP-BSA–coated 
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Multiscreen
 
®
 
 96-well plates (Millipore), and threefold serial dilu-
tions were made before incubation. Plates were incubated for 5 h
at 37
 
 
 
C. After the incubation, plates were washed in 0.05%
Tween 80 and in nano-pure water. ASCs detected by alkaline
phosphatase–conjugated anti–mouse IgG (Southern Biotechnol-
ogy Associates, Inc.). ELISPOTs were developed by a FAST
BCIP/NBT (Sigma-Aldrich) chromagen substrate. ELISPOTs
were enumerated via a ImmunoSpot
 
®
 
 software (CTL Analyzers
LLC) or by direct visual counting using a dual-axis light-dissect-
ing microscope.
 
Real-time RT-PCR.
 
B cells were positively selected (
 
 
 
90%
purity) using biotinylated anti-B220 Ab followed by streptavidin-
coupled microbeads (Miltenyi Biotec). Purified B cells were stim-
ulated with FGK45, an agonistic rat IgG2a anti–mouse CD40
antibody (17), in vitro for 60 h. Purified PCs were isolated by pos-
itive selection using 
 
 
 
CD138 and magnetic beads, followed by
electronic cell sorting for B220
 
 
 
Ly6c
 
 
 
CD138
 
 
 
 cells to a purity of
 
 
 
90%. Total RNA was isolated from either purified B cells, FGK
blasts, or PCs using TRIzol (Invitrogen) followed by secondary
purification over RNeasy columns (QIAGEN) with a DNase-I
treatment step. 1 
 
 
 
g of DNA-free RNA was reverse transcribed
to cDNA using Omniscript RT (QIAGEN). Real-time PCR was
performed with the SYBR Green PCR Core Kit (Applied Bio-
systems) on an iCycler iQ instrument (Bio-Rad Laboratories).
Amplification conditions were 95
 
 
 
C for 8 min, followed by 40
cycles of 94
 
 
 
C for 15 s, 63
 
 
 
C for 45 s, and 72
 
 
 
C for 15 s. Primers
for the control gene mouse 
 
 
 
-actin were as follows: forward, 5
 
 
 
-
CCAATGTGTCCATGTCATTT-3
 
 
 
 and reverse, 5
 
 
 
-CAATA-
GTGATGACCTGGCCGT-3
 
 
 
. Other primers used were as fol-
lows: BCMA, forward, 5
 
 
 
-ATCTTCTTGGGGCTGACCTT-3
 
 
 
and reverse, 5
 
 
 
-CTTTGAGGCTGGTCCTTCAG-3
 
 
 
; BAFF-R,
forward, 5
 
 
 
-CCCCAGACACTTCAGAAGGA-3
 
 
 
 and reverse,
5
 
 
 
-AGGTAGGAGCTGAGGCATGA-3
 
 
 
; TACI, forward, 5
 
 
 
-
GTGTGGCCACTTCTGTGAGA-3
 
 
 
 and reverse, 5
 
 
 
-CTGGT-
GCCTTCCTGAGTTGT-3
 
 
 
; Bcl2, forward, 5
 
 
 
-CTTAGAAA-
ATACAGCATTGCGGAG-3
 
 
 
 and reverse, 5
 
 
 
-GGATGTGCT-
TTGCATTCTTGG-3
 
 
 
; Mcl1, forward, 5
 
 
 
-GCTCCGGAAA-
CTGGACATTA-3
 
 
 
 and reverse, 5
 
 
 
-CCCAGTTTGTTACGC-
CATCT-3
 
 
 
; and Bcl
 
xl
 
, forward, 5
 
 
 
-TTCGGGATGGAGTAA-
ACTGG-3
 
 
 
 and reverse, 5
 
 
 
-TGCAATCCGACTCACCAATA-
3
 
 
 
. Relative RNA expression was determined using the formula
relative expression 
 
 
 
 2
 
 
 
(
 
  
 
CT)
 
 
 
 
 
 1,000, where 
 
  
 
CT 
 
  
 
(cycle
threshold [CT] gene of interest 
 
 
 
 CT 
 
 
 
-actin in experimental
sample) 
 
 
 
 (CT gene of interest 
 
 
 
 CT 
 
 
 
-actin in a no-template
control sample) (see the 
 
  
 
CT method, Taqman
 
®
 
 Bulletin 2: Ap-
plied Biosystems).
 
Online Supplemental Material. 
 
Fig. S1 demonstrates that
APRIL, also a ligand for TACI and BCMA, enhanced the sur-
vival of BM PCs in vitro. Fig. S2 shows that BCMA
 
   
 
 mice
have normal numbers of peripheral B cells, and generate normal
TD immune responses, including GC formation and Ag-specific
serum IgM and IgG titers compared to wild-type controls. On-
line supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20031330/DC1.
 
Results and Discussion
 
BLyS Sustains BM PC In Vitro.
 
It has been shown that
during the later stages of an immune response, the majority
of PCs within the BM are long lived (21–23). Because
BLyS has been shown to be a key survival factor for B cells
in general, and recent transcriptional profiling has shown
increased expression of BCMA on PCs, we asked whether
BLyS could contribute to the survival of BM PCs (24). To
this end, BM from mice 30 d after immunization with PE
was isolated and cultured with IL-6 and/or BLyS for 10 d.
As reported previously (2), and shown here, the addition of
IL-6 can enhance Ag-specific PC survival over short time
intervals (2–4 d); however, over extended time periods (10
d), IL-6 was not effective (Fig. 1 A). The addition of BLyS
alone exerted a modest twofold effect on 
 
 
 
PE ASC sur-
vival over 10 d, but in combination with IL-6, it enhanced
the number of ASCs on day 10 over fourfold (from 
 
 
 
200
to 800 ASCs).
Endogenous BLyS produced by BM cells, such as mac-
rophages or DCs, could contribute to the maintenance of
BM PCs. To analyze the impact of endogenous BLyS on
BM PC survival, whole immune BM was cultured from
immune mice in the presence or absence of TACI-Ig. Pre-
vious papers have demonstrated the ability of TACI-Ig to
block BLyS ligand–receptor interactions (6, 19). The addi-
Figure 1. BLyS and IL-6 enhances BM PC survival in vitro. After a
6–8-wk immunization with 10  g PE, whole BM samples were isolated
from BALB/c and cultured in vitro with the indicated stimuli for a period
of 10 d. (A) After isolation of whole BM samples, 8   106 BM cells were
cultured in medium alone ( ), 200 ng/ml BLyS ( ), 500 pg/ml IL-6
( ), IL-6 and BLyS (X), or 10  g/ml TACI-Ig ( ). At days 2, 4, 7, and
10 of in vitro culture, samples were isolated, and the number of PE-
specific IgG BM ASCs was enumerated by ELISPOT. These data are
representative of four experiments. (B) Immune BM was cultured as in A,
and on day 7, samples were stained with  B220,  CD138, and  Ly6C
antibodies to estimate the number of total PCs (B220 CD138 Ly6C ) in
culture. Two representative experiments out of four are shown.BCMA Is Essential for PC Survival 94
tion of TACI-Ig inhibited the maintenance of BM PCs in
vitro (Fig. 1 A). TACI-Ig reduced the total number of PE-
specific ASCs recovered on day 10 approximately fourfold
compared with serum-only cultures. Moreover, there was a
 17-fold decrease in the number of recovered ASCs on
day 10 in TACI-Ig–treated cultures compared with the ad-
dition of IL-6 and BLyS, clearly showing a critical role of
BLyS in PC survival. Confirmation that BLyS and IL-6
could sustain ASCs was provided by analysis of the total
number of recovered B220 CD138 Ly6C  from cultures
on day 10 (Fig. 1 B). The two representative datasets show
that compared with medium alone, BLyS and IL-6 en-
hances the recovery of PCs three to fourfold. Because
APRIL is also a ligand for both TACI and BCMA, we ad-
dressed whether APRIL, like BLyS, could enhance the sur-
vival of BM PCs in vitro. As shown in Fig. S1 (available at
http://www.jem.org/cgi/content/full/jem.20031330/DC1),
APRIL enhanced the number of PCs in culture alone or in
conjunction with IL-6.
TACI-Ig Impairs the Survival of PCs In Vivo. The im-
portance of BLyS and APRIL to in vivo PC survival was
addressed by blocking these ligands in vivo by the adminis-
tration of TACI-Ig to immune mice. Immune mice, in
which a stable population of long-lived BM PCs was
present, were treated with TACI-Ig or control Ig for a pe-
riod of 14 d. After treatment, the number of ASCs in the
spleen, LN, and BM was determined. TACI-Ig treatment
diminished the recovery of ASCs by 65% in the BM, with
similar reductions in number in the spleen and LN (Fig. 2).
These data corroborate the in vitro data suggesting that
BLyS and/or APRIL are important for the survival of long-
lived PCs.
PCs Bind BLyS and Selectively Up-regulate mRNA for
BCMA but Not TACI or BAFF-R. Data show that BLyS
and/or APRIL can sustain PC survival in vitro, and con-
tribute to PC persistence in vivo. To determine if PCs can
bind BLyS, immune BM was incubated with biotinylated
BLyS, and binding was ascertained by flow cytometry using
fluorochrome-coupled avidin. As can be seen in Fig. 3 A,
binding of biotinylated BLyS could be readily detected on
B220 CD138  cells in the BM. Only first-decade staining
was observed with biotinylated irrelevant control protein
(bio-Ig; unpublished data). Levels of binding to PCs were
Figure 2. Blockade of BLyS via TACI-Ig inhibits PC survival in vivo.
Approximately 6–8 wk after immunization with PE-CFA, immune mice
(four mice/group) were treated with 100  g TACI-Ig or human Ig every 3 d
for a period of 2 wk. After the 2-wk period of treatment, BM, lymph
node (LN), or spleen (SP) tissue samples were isolated from treated mice,
and the number of  PE IgG ASCs was determined by ELISPOT analysis.
Standard error was calculated between values from four independent
mice for each treatment group. Data are representative of three indepen-
dent experiments.
Figure 3. (A) PCs express BLyS receptor. Immune BM and spleen (SP)
was isolated and stained with  CD138,  B220, and biotinylated BLyS.
Histograms of BLyS receptor expression are shown for B220 CD138 
cells (red); B220 CD138  cells (green); and B220 CD138  cells (blue).
Data are representative of three independent experiments. (B) BM PCs
express heightened levels of BCMA mRNA but not BAFF-R or TACI.
RNA from splenic B cells (B cells),  CD40-induced B cell blasts ( CD40
B), or BM PCs (PC) was isolated via the TRIzol method. Real-time RT-
PCR was performed with each sample to evaluate the relative levels of
mRNA expression for BCMA, TACI, and BAFF-R. Data are representative
of three experiments. (C) BLyS enhances Mcl-1 expression in PCs but
not B cells. Purified CD138  BM PCs or splenic B cells were cultured
with the indicated stimulus, as described in Fig. 1. After 18 h, RNA was
isolated, and the relative expression of antiapoptotic genes was deter-
mined relative to  -actin.O’Connor et al. 95
similar to those observed on mature B cells (B220 ) in the
spleen. We also observed higher levels of BLyS binding in
the non–B cell compartment in the BM compared with the
spleen. We suspect that this may be due to BLyS-R/
TACI/BCMA expression by developing B cells present in
the BM. Therefore, it is clear that long-lived PCs express a
BLyS receptor.
To gain initial insights into which of these receptors may
be functionally important in PC survival, real-time PCR
analysis was use to evaluate receptor mRNA expression in
PCs. BM PCs were purified via magnetic bead and FACS®
sorting ( 94% CD138 , B220 ) and processed for real-
time PCR analysis of mRNA. We observed that BM PCs
express high levels of message for BCMA compared with
resting B cells, and similar levels to that observed in
 CD40-activated B cells (Fig. 3 B). In contrast, PCs ex-
pressed much lower levels of BAFF-R and TACI com-
pared with both resting B cells and  CD40-activated B
cells. These data confirm the heightened levels of BCMA
expressed by PCs (or multiple myeloma) as deduced by
transcriptional profiling (17, 24).
To begin to unravel the mechanism of BLyS-induced
PC survival, the transcriptional expression of a number of
 -apoptotic gene products was evaluated after BLyS stimu-
lation or IL-6 stimulation of purified B cells and PCs. As
can be seen in Fig. 3 C, BLyS up-regulated Bcl2 transcript
expression in B cells but not in PCs. This is consistent with
the observed increase of Bcl2 in B cells from the BLyS
transgenic mice (25). In contrast, levels of Mcl-1 expressed
in B cells was reduced by BLyS and increased by either
BLyS or IL-6 in PCs, whereas Mcl-1 has been suggested
important in PC survival (26, 27).
BCMA Is Critical for Long-Term Survival of BM PCs.
The heightened expression of BCMA and the capacity of
BLyS to support PC survival suggested that BCMA may be
critical for PC survival. To test this hypothesis, BCMA / 
and WT mice (BCMA / ) were immunized, and the
number of ASCs in the BM was evaluated 6–8 wk after
immunization. As can be seen in Fig. 4, compared with
WT mice, the BCMA /  mice had  20% of the number
of ASCs and indicate a critical role of BLyS and BCMA in
BM PC survival. The decrease of ASCs in BCMA /  mice
is not due to impaired TD humoral immune responses, as
these mice showed normal numbers of peripheral B cells,
GC responses, and Ag-induced serum IgM and IgG titers
(Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20031330/DC1).
Sustained humoral immune responses depend on the
persistence of long-lived BM PCs. The studies discussed
show that the BLyS–APRIL-BCMA pathway plays a role
in this function. The data show that both BLyS and APRIL
in conjunction with IL-6 can sustain the survival of PCs in
vitro, and that these ligands are likely survival factors for
PCs in vivo. Because TACI-Ig can functionally block both
BLyS and APRIL, conclusive identification of the active
ligand in vivo awaits additional studies. Be it BLyS or
APRIL as the functional ligand in PC survival, the studies
presented implicate BCMA as the receptor that controls
the lifespan of BM PCs.
The data show that TACI-Ig treatment causes a decay in
a preexisting population of long-lived PCs. Tangye et al.
have recently shown that BLyS and APRIL can selectively
enhance survival of plasmablasts generated from human
memory B cells in vitro (28). We, too, have seen an effect
on PC precursors (unpublished data); however, this effect
on plasmablasts cannot account for the decay of ASCs seen
in the studies presented. It is clear that BM PCs have an in-
trinsic half-life in months, so impairing precursor function
cannot explain the precipitous decline in ASCs in TACI-
Ig–treated mice. Furthermore, it is shown that PCs bind
BLyS, suggesting that TACI-Ig impairs PC survival via a
direct effect on PCs and not their precursors. Affirmation
that APRIL can influence humoral immunity in vivo is
provided by the enhanced humoral immune responses ob-
served in APRIL transgenic mice (29).
We also demonstrate that BM PCs express heightened
levels of mRNA for BCMA compared with B cells (Fig. 3
B). Our data corroborate earlier papers, which report
heightened PC expression of BCMA compared with other
B cell subsets by transcriptional profiling (30, 31). Very re-
cently, Novak et al. reported the expression of BCMA on
primary multiple myeloma and myeloma cell lines, but not
on resting or memory peripheral B cell populations in hu-
mans, suggesting that the expression of BCMA occurs late
in the course of B cell differentiation (32). Given the
greatly reduced expression of BAFF-R and TACI in PCs
compared with other B cell subsets and the heightened ex-
pression of BCMA, it suggests that BCMA may be the vital
receptor for PC survival in the BM. Studies in BCMA / 
mice demonstrate that long-term PC survival was impaired
in the absence of BCMA, providing conclusive functional
importance of BLyS–APRIL-BCMA interactions. Previous
studies in the BCMA /  mice did not examine long-term
PC survival. Interestingly, the BCMA /  mice have been
reported to show no defects in short-term production of
Ig, GC formation, and immune architecture (13). We, too,
Figure 4. BCMA    mice have a reduced capacity to sustain long-
lived BM PCs. BCMA /  (WT) and BCMA /  mice were immunized
with 100  g of alum-precipitated (4-hydroxy-3-nitrophenyl)acetyl
chicken   globulin for 7 wk. The number of NP-specific IgG ASCs in
the BM was quantified by antigen-specific ELISPOT analysis. The deter-
mined p-value   0.00094 and is representative of two experiments each
with three mice/group.BCMA Is Essential for PC Survival 96
evaluated many of these same parameters in the BCMA / 
mice and have concluded that B cell development, early
humoral immune responses, and GC responses were indis-
tinguishable from WT mice.
The manner through which BCMA ligation enhances
BM PC survival is currently unknown; however, the up-
regulation of Mcl-1 in PCs by BLyS is intriguing because
Mcl-1 has been implicated in the survival of activated B
cells and PCs (26, 27). As a survival receptor, structurally,
BCMA is most similar to BAFF-R and not TACI (33, 34),
consistent with the emerging functional similarities that
both BAFF-R and BCMA function to promote B cell sur-
vival at distinct stages of B cell development. In contrast,
TACI has been suggested to be a negative regulator of B
cell activity and BAFF-R signaling.
In conclusion, BLyS or APRIL, two newly identified
members of the TNF family, are necessary for the survival
of long-lived BM PCs. Although BCMA appears to play lit-
tle to no role in many of the events leading up to the forma-
tion of long-lived PCs, it certainly seems to play a role in
their survival. Perhaps the most exciting aspect of the role of
BCMA in PC survival is the recognition that therapeutic
targeting of BCMA may be an effective way to selectively
eliminate PCs in antibody-mediated autoimmunity.
This work was supported by National Center for Research Re-
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